Literature DB >> 17199027

Talampanel.

John F Howes1, Cynthia Bell.   

Abstract

Talampanel is a novel anticonvulsant that acts as an allosteric inhibitor of the AMPA receptor. Talampanel has a broad spectrum of action in animal models of epilepsy and neuroprotection. Clinical experience to date has been able to show effectiveness in reduction of seizures in patients with refractory partial seizures.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17199027     DOI： 10.1016/j.nurt.2006.11.001

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN： 1878-7479            Impact factor:   7.620


  21 in total

1.  Unified pharmacogenetics-based parent-metabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans.

Authors:  Peter Buchwald; Attila Juhász; Cynthia Bell; Márta Pátfalusi; John Howes; Nicholas Bodor
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

2.  The AMPA-antagonist talampanel is neuroprotective in rodent models of focal cerebral ischemia.

Authors:  Franciska Erdo; Pál Berzsenyi; Ferenc Andrási
Journal:  Brain Res Bull       Date:  2005-04-21       Impact factor: 4.077

3.  The AMPA/kainate receptor antagonist, LY 300164, increases the anticonvulsant effects of diazepam.

Authors:  K K Borowicz; Z Kleinrok; S J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-06       Impact factor: 3.000

Review 4.  AMPA receptors in epilepsy and as targets for antiepileptic drugs.

Authors:  M A Rogawski; S D Donevan
Journal:  Adv Neurol       Date:  1999

5.  Stereoselective effects-of 2,3-benzodiazepines in vivo: electrophysiology and neuroprotection studies.

Authors:  D Lodge; A Bond; M J O'Neill; C A Hicks; M G Jones
Journal:  Neuropharmacology       Date:  1996       Impact factor: 5.250

6.  Influence of LY 300164, an AMPA/kainate receptor antagonist upon the anticonvulsant action of antiepileptic drugs against aminophylline-induced seizures in mice.

Authors:  Mariusz Swiader; Hubert Kuźniar; Zdzisław Kleinrok; Stanisław J Czuczwar
Journal:  Pol J Pharmacol       Date:  2003 Jan-Feb

7.  Effect of two noncompetitive AMPA receptor antagonists GYKI 52466 and GYKI 53405 on vigilance, behavior and spike-wave discharges in a genetic rat model of absence epilepsy.

Authors:  Rita Jakus; Marton Graf; Romeo D Ando; Brigitta Balogh; Istvan Gacsalyi; Gyorgy Levay; Sandor Kantor; Gyorgy Bagdy
Journal:  Brain Res       Date:  2004-05-22       Impact factor: 3.252

8.  Induction of reproducible brain infarction by photochemically initiated thrombosis.

Authors:  B D Watson; W D Dietrich; R Busto; M S Wachtel; M D Ginsberg
Journal:  Ann Neurol       Date:  1985-05       Impact factor: 10.422

9.  Correlation between cerebral blood flow and histologic changes in a new rat model of middle cerebral artery occlusion.

Authors:  H Nagasawa; K Kogure
Journal:  Stroke       Date:  1989-08       Impact factor: 7.914

10.  Influence of the N-acetylation polymorphism on the metabolism of talampanel: an investigation in fasted and fed subjects genotyped for NAT2 variants.

Authors:  P Buchwald; A Juhász; C Bell; M Pátfalusi; P Kovács; G Hochhaus; J Howes; N Bodor
Journal:  Pharmazie       Date:  2006-02       Impact factor: 1.267
View more
  21 in total

Review 1.  Unique biology of gliomas: challenges and opportunities.

Authors:  Stacey Watkins; Harald Sontheimer
Journal:  Trends Neurosci       Date:  2012-06-08       Impact factor: 13.837

Review 2.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

3.  A series of structurally novel heterotricyclic alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptor-selective antagonists.

Authors:  M B Gill; S Frausto; M Ikoma; M Sasaki; M Oikawa; R Sakai; G T Swanson
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 4.  Computational models of neuronal biophysics and the characterization of potential neuropharmacological targets.

Authors:  Michele Ferrante; Kim T Blackwell; Michele Migliore; Giorgio A Ascoli
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 5.  Key factors in the discovery and development of new antiepileptic drugs.

Authors:  Meir Bialer; H Steve White
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

Review 6.  Towards personalized therapy for patients with glioblastoma.

Authors:  Katsuyuki Shirai; Arnab Chakravarti
Journal:  Expert Rev Anticancer Ther       Date:  2011-12       Impact factor: 4.512

7.  Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas.

Authors:  Fabio M Iwamoto; Teri N Kreisl; Lyndon Kim; J Paul Duic; John A Butman; Paul S Albert; Howard A Fine
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

Review 8.  Targeting AMPA and kainate receptors in neurological disease: therapies on the horizon?

Authors:  Geoffrey T Swanson
Journal:  Neuropsychopharmacology       Date:  2009-01       Impact factor: 7.853

9.  AMPA receptors and stargazin-like transmembrane AMPA receptor-regulatory proteins mediate hippocampal kainate neurotoxicity.

Authors:  Susumu Tomita; R Keith Byrd; Nathalie Rouach; Camilla Bellone; Angela Venegas; Jessica L O'Brien; Kwang S Kim; Olav Olsen; Roger A Nicoll; David S Bredt
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-13       Impact factor: 11.205

10.  Early alterations of AMPA receptors mediate synaptic potentiation induced by neonatal seizures.

Authors:  Sanjay N Rakhade; Chengwen Zhou; Paven K Aujla; Rachel Fishman; Nikolaus J Sucher; Frances E Jensen
Journal:  J Neurosci       Date:  2008-08-06       Impact factor: 6.167
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.